Adult hematopoietic stem cells (HSCs) maintain tissue homeostasis and regenerative capacity of the hematopoietic system through self-renewal and differentiation. Metabolism is recognized as an important regulatory entity controlling stem cells. As purine nucleotides are essential for metabolic functions, we analyzed the role of hypoxanthine guanine phosphoribosyl transferase (HPRT)associated purine salvaging in HSCs. Here, we demonstrate that hematopoietic stem and progenitor cells (HSPCs) show a strong dependence on HPRT-associated purine salvaging. HSPCs with lower HPRT activity had a severely reduced competitive repopulation ability upon transplantation. Strikingly, HPRT deficiency resulted in altered cell-cycle progression, proliferation kinetics and mitochondrial membrane potential primarily in the HSC compartment, whereas more committed progenitors were less affected. Our data thus imply a unique and important role of HPRT and the purine salvage pathway for HSC function. STEM CELLS 2019;37:1606-1614 
INTRODUCTION
Hematopoietic stem cells (HSCs) are able to self-renew and differentiate into all blood cell lineages to maintain homeostasis and regeneration. Metabolism has emerged as an important regulatory entity influencing the function and the potential of HSCs [1] . HSCs are primarily quiescent and show low mitochondrial activation and function but high levels of glycolysis [2] [3] [4] [5] . Upon stress like for example blood loss, HSCs switch to oxidative phosphorylation to enter the cell cycle to undergo self-renewal and differentiation [6] . Recently, the activation of the purine nucleotide metabolism in HSCs could be linked to HSCs activation in response to stress [7] . Because purine nucleotides are not only direct components of DNA and RNA but as they are actually involved in almost all metabolic processes, they might be critical for both quiescent as well as proliferating cells.
Cells obtain purine nucleotides via either de novo synthesis or salvaging of free purine bases (aka recycling) [8] (Fig. 1A) . These pathways differ in terms of energy consumption: The de novo synthesis of ATP and GTP requires an energy equivalent provided by the hydrolysis of 10 ATP molecules, yet, the purine salvage pathway only requires six ATP units [9] . Most organ systems and several cell lines prefer the salvage pathway [10, 11] ; and thus recycling. An increase of de novo synthesis is usually observed during cell growth and proliferation and upon malignant transformation [10, 12, 13] . Amidophosphoribosyltransferase (PPAT) catalyzes the first and rate limiting step of de novo synthesis in which 5 0phosphoribosyl-1-pyrophosphate (PRPP) serves as the starting substrate. Free purine bases can be recycled by hypoxanthine guanine phosphoribosyl transferase (HPRT, guanine and hypoxanthine) and adenine phosphoribosyltransferase (APRT, adenine), or they can be degraded to uric acid by xanthine oxidase.
HPRT is ubiquitously expressed and catalyzes the conversion of hypoxanthine to IMP and guanine to GMP via transfer of the 5-phosphoribosyl group from PRPP [14] . APRT converts adenine in the same manner. The hprt1 gene is located on the X-chromosome and highly conserved between mice and humans [15] . Partial HPRT deficiency results in gouty arthritis, whereas an almost complete deficiency leads to the Lesch-Nyhan disease. The latter is characterized by severe neurological dysfunction in addition to gouty arthritis, including retardation, choreoathetosis, and aggressive and compulsive self-mutilation. Whether there are HSC phenotypes in these diseases have not been investigated in detail. Bone marrow (BM) cells express low levels of Ppat and high levels of Hprt [14] . HSCs show the highest level of HPRT expression right after active CD8 positive T-cells [16] which might imply a critical role of HPRT-driven purine salvaging for HSCs. In this study, we demonstrate that a reduced level and activity of HPRT, which results in impaired purine salvaging in HSCs, resulted in a reduced function of HSCs. Additionally, HSCs with reduced levels of HPRT were altered in cell-cycle progression, proliferation kinetics, and mitochondrial function, whereas hematopoietic progenitors were only marginally affected. Our data reveal that HSCs strongly depend on HPRT-associated purine salvaging to maintain the function and the potential of HSCs.
MATERIALS AND METHODS
Mice C57BL/6J mice were obtained from Janvier (Le Genest-Saint-Isle, France) or from our on-site breeding cohort (based on C57BL/6 animals from Janvier). Breeding pairs for B6.SJL-Ptprc<a>Pepc<b>/ BoyJ recipient mice were obtained from Charles River (Wilmington, MA, USA). The HPRT low mouse model (B6xB6 Tgh (EGFP) Brl (−/−)) was kindly provided by Klaus Schwarz, and the HPRT knockout mice were a gift from Erich Schneider. All mice were bred and housed under specific pathogen-free conditions at the Tierforschungszentrum of Ulm University. The experiments were performed in compliance with the German Law for Welfare of Laboratory Animals and were approved by the Regierungspräsidium Tübingen (TVA). For HPRT low mice, peripheral blood (PB) smears from male mice were analyzed for the transgene by fluorescence microscopy using a GFP fluorescence filter. Only male mice were used in the experiments.
Reagents and Standard Procedures
Hanks' balanced salt solution (HBSS) (BioWhittaker Lonza, Basel, Switzerland) and Iscove's Modified Dulbecco's Medium (IMDM) (BioWhittaker Lonza) were supplemented with 10% fetal bovine serum (FBS) (Hy-Clone Fetal bovine serum defined; Thermo Scientific, Waltham, MA, USA) and 1% penicillin/streptomycin if not otherwise specified. Femora, tibiae, and hip bones were flushed to obtain total BM. If needed, mononuclear cells (LDBM) were isolated by low density centrifugation (26 minutes, RT, no brake/acceleration) on Histopaque-1083 (Sigma-Aldrich, St. Louis, MO, USA). If not otherwise described, LDBM cells were directly used for experiments (steady state) and partly were in vitro stimulated with cytokines for 48 hours (37 C, 21% O 2 and 5% CO 2 in IMDM +1% GlutaMax (Gibco, Thermo Scientific) + 50 ng/ml murine SCF (Prospec-ProteinSpecialists, Rechovot, Israel) + 100 ng/ml Flt-3 (Prospec-ProteinSpecialists) + 100 ng/ ml TPO (Prospec-ProteinSpecialists) (Stimulated state).
Hematopoietic Progenitor Cell Staining
To LDBM cells, biotin-labeled lineage-antibody cocktail was added (Table S1) or LDBM was lineage depleted by using a mouse lineage depletion kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol with the following adaptions: we used 20 μl/10 7 cells of the beads and cells were resuspended at a concentration of 3 ml/10 7 cells. After washing, FC-Block anti-mouse CD16/CD32 Clone 93 (eBioscience, CA, USA) was added. For the staining, Streptavidin, anti-CD34, anti-Sca-1, and anti c-Kit were added for 1 hour at 4 C in the dark (Table S1 ).
Quantitative Real-Time PCR
Total RNA was isolated either from FACS (Aria III, BD Biosciences, Franklin Lakes, NJ, USA) sorted HSPCs or eGFP + and eGFP − LDBM cells using the RNeasy Micro-Kit (Qiagen, Hilden, Germany). HSPCs cells were processed either directly after sorting (steady state) or after 16 hours stimulation. in vitro stimulation of HSPCs was induced by a 16 hours incubation at 37 C, 21% O 2 and 5% CO 2 in IMDM +1% GlutaMax + 50 ng/ml murine SCF + 100 ng/ml Flt-3 + 100 ng/ml TPO. A maximum of 500 ng of RNA was used for cDNA synthesis (QuantiTect Reverse Transcription Kit; Quiagen). Normalization was made with Gapdh and fold change was calculated by ΔΔCt (Delta delta Ct) method, in which wild type (WT) or HPRT were used as baseline (=1), for more details see supplement.
Western Blot
In all, 5 × 10 5 LDBM cells were used for protein extraction. Antimouse actin antibody (clone: AC-15, Sigma-Aldrich, 1:1,000) was used to identify actin. The strength of the actin signal was used to normalize for differences in gel loading. Anti-rabbit HPRT clone: FL-218 (SantaCruz Biotechnology, Dallas, TX, USA) for the target (1:200). Secondary antibodies donkey anti-mouse IG-HRP sc-2314 and donkey anti-rabbit IG-HRP sc-2077 were added at 1:10,000. Band intensities were quantified with ImageJ software. 
6-Thioguanin (6-TG) and Aminopterin (Ao) Survival Assay
LDBM cells were incubated for 48 hours with different dosages of 6-TG (Sigma-Aldrich) or Ao (Sigma-Aldrich). Conditions: 37 C, 21% O 2 , 5% CO 2 in IMDM +1x GlutaMax + 50 ng/ml murine Stem Cell Factor + 10 ng/ml Interleukin-3 mouse (Prospec-Pro-teinSpecialists) + 100 ng/ml Interleukine-11 mouse (Prospec-Pro-teinSpecialists) + 100 ng/ml Flt-3 for Ao treatment additionally 16 μM Thymidine (Sigma-Aldrich) was added. Used dosages ranges of 6-TG or Ao were: 0.05-50 μM and 0.0001-10 μM. Afterward LDBM cells were stained with antibodies to define hematopoietic stem and progenitor cells. Before samples were analyzed by a BD LSR II, Propidium iodide (PI) (1 μg/ml) (Sigma-Aldrich) was added for live/dead staining. The survival rate was calculated by subtracting the percentage of PI + cells. Normalization was performed using 0 μM 6-TG/Ao = 100% alive cells. Curve fitting was performed with the software suite Prism 7.0 and a nonlinear fit: log(inhibitor) versus response variable slope.
Staining of PB and Total BM
PB was collected by cardiac puncture after euthanizing mice with CO 2 or in case of transplantation experiments from the facial vein. Total BM was collected by flushing femora, tibiae, and hip bones. Staining was performed with anti-CD3e, anti-B220, anti-Gr-1, and anti-Mac-1. For transplanted animals, anti-Ly5.2 and anti-Ly5.1 were used to identify donor and recipient cells. Red cell lysis was performed and cells were analyzed on a LSR II flow cytometer (BD Bioscience). Data are plotted as the percentage of B-cells (B220 + ), T-cells (CD3 + ), and myeloid (Gr-1 + , Mac-1 + and Gr-1 + , Mac-1 + ) cells among donor-derived Ly5.2 + cells regarding transplantation experiment or among total white blood cells (antibodies Table S1 ).
Transplantation
Hematopoietic progenitor cell staining was performed on lineage depleted WT or HPRT low Ly5.2 cells. HSPCs were subsequently sorted on a FACS (Aria III, BD Biosciences) and kept overnight at 37 C, 5% CO 2 , 3% O 2 in IMDM. The next morning 1,000 LSK (Ly5.2) along with 3 × 10 5 freshly prepared total BM competitor cells (Ly5.1) were transplanted into the tail vein of each lethally irradiated (7 + 4 Gy) mouse. Ly5.2/Ly5.1 chimerism in PB was monitored every 4 weeks. At least 20 weeks after transplantation, early hematopoiesis/total BM and PB staining was performed.
Cell-Cycle Analysis
Staining was performed with the BrdU flow kit (BD Pharmingen) as described previously [17] .
Single-Cell Proliferation Kinetics
Terasaki plates (Greiner Bio one, Kremsmuester, Austria) were prepared by adding 20 μl of IMDM +10% FBS + 1% 100X Penicillin/Streptomycin +100 ng/ml murine SCF + 100 ng/ml G-CSF + 100 ng/ml TPO (all Prospec-ProteinSpecialists). HSCs were sorted into Terasaki plates, one single HSC in each well. After 1 hour, the count of correctly filled wells was determined. Terasaki plates were incubated for 48 hours at 3% O 2 , 5% CO 2 and 37 C. Cell division was observed every 4-8 hours. For first division, all wells were counted with at least two cells.
TMRM and MitoSox
First, hematopoietic progenitor cell antibody panel staining was performed on LDBM cells. After staining, 50 nM TMRM (Invitrogen, Carlsbad, CA, USA) or 5 μM of MitoSox (Invitrogen) were added. Samples were incubated for 30 minutes at 37 C + vortex in the dark and washed with HBSS. Samples were measured by a BD LSRFortessa flow cytometer (BD Bioscience). Data are represented as fold change, calculated by dividing mean TMRM fluorescence measured in HPRT low cells through the mean TMRM fluorescence from the WT cells (three mice/n, WT and HPRT low cells were treated the same and measured in the same experiment).
ATP and ADP Amounts
Hematopoietic progenitor staining on lineage depleted cells was performed. Lin + cells were washed out of the lineage depletion kit column (Miltenyi Biotec). HSCs and early progenitor cells were sorted by FACS (Aria III, BD Biosciences) and either used directly after sort or cells were stimulated for 16 hours before performing ATP/ADP measurement (Sigma-Aldrich). For the ATP/ADP ratio, assay cells were washed (PBS) and resuspended at a concentration of 10 5 /ml PBS, final 1,000 cells/well. Protocol of ATP/ADP ratio kit was followed, exception: ATP reagent was added to the wells and a background measurement was performed before adding the cell extract. Relative luminescence units were measured with standard luminescence on a Paradigm Detection Platform (Beckman Coulter, Brea, CA, USA). Data are plotted as fold change (see also analysis TMRM above).
Annexin V
Hematopoietic progenitor cell staining was performed with LDBM cells. Afterward, 5 μl of Anti-Annexin V antibody (BD Pharmingen) dissolved in 200 μl of Annexin V binding buffer was applied for 20 minutes at RT in the dark. Before analyzing by BD LSRFortessa (BD Bioscience), PI live/dead staining was used.
Data Analysis and Statistics
Data were assumed to meet normal distribution. If not otherwise stated data are displayed as means +1SEM. All statistical analyses were performed with the Graph Pad Prism 7 Software Suite. Correction for multiple comparison was performed using Sidak or Tukey Test (ANOVA) or Holm-Sidak method (t test). The number of biological repeats (n) is listed in figure legends.
RESULTS

HSPCs Depend on Purine Salvaging
We first determined the level of expression of the key players linked to the two pathways of purine metabolism. A general overview on the purine metabolism pathway is provided in Figure 1A , whereas gating strategies to define the distinct hematopoietic cell populations are illustrated in Figure S1 . We then identify the relative enzymatic activity of the HPRT-driven salvage pathway versus the de novo synthesis in primitive hematopoietic cells using pharmacological suicide assays. Cells are killed by 6-thioguanine (6-TG) when it is metabolized by HPRT. Ao is a folate metabolism inhibitor that reduces nutrients for purine de novo synthesis. Cell death in response to Ao is thus an indication of the activity of purine de novo synthesis. HSCs were quite www.StemCells.com sensitive to 6-TG with a survival rate of only 30% at a 10 μM concentration ( Fig. 1B) , whereas sensitivity to Ao was moderate, with more than 75% of cells surviving at a concentration of 10 μM (Fig. 1C) . These data imply that HSCs primarily use the HPRT-dependent purine salvage pathway. Interestingly, early hematopoietic progenitor cells showed significantly reduced survival in response to both drugs, implying that early progenitors and thus cells that are only slightly more differentiated than HSCs use in addition to the salvage pathway also purine de novo synthesis (Fig. 1B, 1C) . Interestingly, differentiated cells (Lin + ) exhibited the highest level of cells surviving both treatments, which implies a low need for purines in differentiated cells or they use pathways independent of HPRT and PPAT (Fig. 1B, 1C) . As already implied previously [16] , Hprt mRNA expression in HSPCs (LSK cells) was slightly elevated compared with the expression of both Ppat and Aprt in steady state (Fig. 1D ), but similar upon activation by cytokines ( Fig. 1E ), demonstrating that the expression level of these genes might not be linked to the distinct usage of these pathways in primitive hematopoietic cells.
To further investigate the role of HPRT-mediated purine salvaging for HSCs, we analyzed hematopoietic cells from a novel mouse strain in which the level of expression of HPRT is significantly reduced compared with the expression in WT control animals (HPRT low animals). In this strain, an eGFP cassette was inserted at the hprt1 gene locus under the control of the human elongation factor-1α promotor (Fig. S2A ). Due to mechanisms currently not understood, only approximately 80% of all types of blood cells express eGFP in these hemizygous mice, translating into eGFP + and eGFP − hematopoietic cells (Fig. S2B ). The integration of this cassette resulted in reduced levels of HPRT, both with respect to RNA ( Fig. 1F ) and protein (Fig. 1G) . Interestingly, eGFP + hematopoietic cells, in comparison with eGFP − cells, presented with a slightly higher but still overall low level of expression of HPRT, generating a system with graded levels of reduction of HPRT levels in hematopoietic cells. To confirm also the loss of HPRT activity in hematopoietic cells from these animals, a 6-TG assay was performed ( Fig. 1H ). HSCs, early progenitors, and Lin + cells showed, compared with control cells, increased survival in response to 6-TG, confirming reduced activity of HPRT and thus reducing activity of the purine salvage pathway in hematopoietic cells from HPRT low mice.
Hematopoietic Cells Do Not Elevate Purine De Novo Synthesis to Compensate for the Loss of Purine Salvaging
We then asked whether primitive hematopoietic cells might increase de novo synthesis of purines in case of the compromised purine salvaging pathway. To this end, we first determined the level of expression of purine metabolism-related enzymes in WT and HPRT low HSPCs in steady state as well as after stimulation with cytokines for 16 hours ( Fig. 2A, 2B ). In general, there were only none or minor differences in the level of expression of enzymes linked to the de novo synthesis or the APRT-associated salvage pathway (like Ppat, Rrm, Impdh2, Ampd2, Aprt) in either steady state or after stimulation ( Fig. 2A, 2B ). Thus, low levels of HPRT do not result in compensatory changes in expression of genes in the purine metabolism pathway. We next tested whether HPRT low HSCs and early progenitors might be more susceptible to killing induced by Ao, which might imply an increase in the activity of the de novo synthesis pathway. Interestingly, HSCs, early progenitors and Lin + cells from HPRT low mice presented with survival curves in response to Ao that were almost identical to the ones from WT cells (Fig. 2C ). Hematopoietic cells with reduced activity of HPRT and thus an impaired purine salvage pathway (Fig. 1H ) do not elevate purine de novo synthesis in a significant manner.
HPRT low HSCs Show Impaired Engraftment
To examine the influence of reduced HPRT activity and thus impaired purine salvaging on the function of HSCs, we performed competitive transplantation assays and monitored donor chimerism in PB for at least 20 weeks post-transplant as an indicator for the function of transplanted HSCs (Fig. 3A) . Both chimerism in PB driven by transplanted eGFP + or eGFP − HPRT low HSCs was strongly reduced in comparison to chimerism supported by transplanted WT cells (Fig. 3B) . HPRT low and WT HSPCs maintained a similar differentiation potential as determined by their relative contribution to myeloid and lymphoid (Tand B-) cells (Fig. 3C) . eGFP − cells, showing the lowest level of HPRT expression, also showed the lowest percentage of contribution to PB (Fig. 3B ). Mirroring the reduced chimerism in blood, the frequency of both HPRT low eGFP − or GFP + derived HSCs and the number of more committed progenitor and differentiated cells (early progenitors, LK, and BM cells) was also reduced in the BM of recipients (Fig. 3D) . Upon secondary transplantation, the percentage of HPRT low donor-derived cells in PB was further reduced. HPRT low eGFP − derived cells were not able to engraft at all whereas HPRT low eGFP + derived cells were further reduced compared with the percentage shown in primary transplants; however, engraftment was constant over time ( Fig. S3) . Similarly, transplantation of HPRT knockout HSPCs also resulted in overall reduced engraftment in PB without a skewing in differentiation (Fig. S4) .
In strong contrast though, HPRT low mice presented with normal hematopoietic parameters in steady state. The frequency of B-, T-, and myeloid cells in both PB (Fig. 3E) and BM (Fig. 3F ) and the frequency of HSC as well as early progenitor cells in BM (Fig. 3G) were similar in WT and HPRT low mice. HPRT low mice presented with a small but significant reduction in the red blood cell count among all the red cell blood parameters determined (Fig. 3H) . These data imply that impaired purine salvaging results in a reduced function of HSPCs upon stress or activation like transplantation, but interestingly not in steady-state hematopoiesis.
HPRT low HSCs Manifest with Changes in Proliferation Kinetics and Reduced Mitochondrial Activity
To further investigate likely mechanisms for the reduced level of engraftment of HPRT low HSPCs, we determined cell-cycle distribution, proliferation kinetics, and the level of apoptosis in primitive hematopoietic cells. First, we observed that the percentage of cells in S-phase was increased in HPRT low HSCs but not in early progenitors and mature cells (Fig. 4A, 4B) . To further test for cell-cycle dynamics, we performed single-cell proliferation kinetics of HSCs. Indeed, HPRT low HSCs also completed their first division faster than their WT counterpart (Fig. 4C) . The percentage of apoptotic cells, including stem, early progenitor, and differentiated cells, did not differ between WT and HPRT low cells as determined by Annexin V staining (Fig. 4D) . A faster progression of HPRT low HSCs through the cell cycle might therefore contribute to their impaired function upon stress.
Additionally, the functional status of mitochondria was investigated, as nucleotide metabolism and energy metabolism might be directly linked. We found that the mitochondrial membrane potential (MMP) was reduced in HPRT low HSCs in steady state (Fig. 4E) . Upon activation (cell-cycle initiation in cultivation for 48 hours with cytokines), MMP was similar in HSC from both WT and HPRT low animals (Fig. 4E ). The level of mitochondrial superoxide (determined by positive staining with the marker MitoSox) was similar in WT and HPRT low cell populations, whereas, upon activation, there was an increased level in HPRT low compared with WT HSCs (Fig. 4F ). Finally, we determined whether low HPRT activity might alter the levels of ATP or ADP in primitive hematopoietic cells, using a sensitive luciferin-based assay (Fig. S5 ). There was a trend toward a slightly decreased ATP concentration in steady-state HPRT low HSCs, whereas in the stimulated state, ATP levels were slightly elevated (Fig. 4G ). The concentration of ADP was equal ( Fig. 4H) with the exception of the slight increase of ADP in differentiated cells after stimulation. In summary, HSCs from HPRT low mice show lower MMP in steady state, but elevated levels of mitochondrial superoxide, and a trend toward higher concentrations of ATP in stimulated state, which might in combination also contribute to the impaired function of HSCs upon transplantation.
DISCUSSION
Our enzyme activity assays and the hprt/ppat gene expression analyses, together with the previously reported finding that PPAT has a lower affinity to PRPP than HPRT [10] , suggest that quiescent HSCs favor HPRT-associated purine salvaging over purine de novo synthesis. Interestingly, our data imply that HSCs do not compensate for reduced purine salvaging activity due to low HPRT levels by increasing purine de novo synthesis. Salvaging might thus be the preferred mechanism to sustain purine metabolism in HSCs-even under stress conditions. HSPCs that show low activity of the purine salvaging pathway caused by low HPRT levels (HPRT low ) present with a reduced engraftment upon transplantation (a stress condition), whereas steady-state hematopoiesis was not affected in HPRT low animals. Upon secondary transplantation, we did not detect a further decrease in the reconstitution potential of HPRT low cells over time. This might imply that the self-renewal potential of HPRT low HSCs might not be always and simply intrinsically affected but the defect shows only under distinct stress conditions which were met upon primary transplantation with only a few number of supporting BM cells as competitors compared with the secondary transplants with a high number of supporting BM cells. A difference in cell intrinsic compensation in HPRT −/− cells compared with HPRT low HSCs might also be the underlying reason for the difference in reconstitution potential of HPRT −/− versus HPRT low HSCs (Figs. 3B and Fig. S4 ). In the complete absence of HPRT in cells of HPRT −/− animals, there was an upregulation of purine nucleotide synthesis [18] and APRT salvaging reported [19] , which we did though not observe in HPRT low cells (Fig. 2) .
One of the key factors influencing HSC fitness is mitochondrial activity, which was reported to be influenced by an imbalance in purine metabolism [20] . Indeed, we found a reduced MMP abundance in steady state as well as elevated mitochondrial superoxide levels in activated HPRT low HSCs. Both factors in combination are indicative of mitochondrial dysfunction. Interestingly though, the concentration of the prime purine derivatives ATP and ADP was similar in hematopoietic cells from WT and HPRT low mice. These findings match observations made in HPRT deficient neuronal cell lines. Here, the amount of all purine nucleotides was not changed, whereas purine nucleotide binding enzymes and mitochondrial function were rather found to be deregulated [20, 21] . Our data support the finding that a reduction in HPRT and thus purine salvaging does not seem to affect the availability of purine nucleotides in HSCs. This would argue against the theory that HPRT deficient cells are selected against because of reduced DNA synthesis and proliferation of stem cells due to loss of purine nucleotides [22, 23] . In fact, our data show that HPRT low HSCs present with an elevated percentage of cells in S-Phase and faster cell division kinetics, which in combination are indicative of reduced quiescence. We rather propose that the phenotype of HPRT low HSCs is due to an elevated usage and thus activation of the degradation pathway of purines rather than a lack of recycling ( Fig. 1A) . For example, elevated levels of the purine degradation product hypoxanthine drive cell-cycle progression in hprt knockout glioblastoma cells [24] . A dysfunction of mitochondria in HPRT low HSCs might also be attributed to elevated usage of purine degradation. High activity of xanthine oxidase, which is one of the key enzymes important for degradation of purines ( Fig. 1A) , has been associated with high levels of mitochondrial ROS production [25] . Unfortunately, direct measurements of purine degradation in HSCs are technically not yet possible, given the low number of HSCs per animal. Still, our data support the notion that the balance between purine salvaging and de novo synthesis is not necessary a question of stabilizing the purine nucleotide pool but might be a way of minimizing toxic waste products. Our findings also question whether HPRT negativity might be used as a selection marker for HSCs for downstream transplantation applications in gene therapy protocols [26] .
SUMMARY
We have identified the HPRT-associated purine salvaging pathway as a critical contributor to HSC fitness in response to stress. Additionally, we provide evidence that the preference for HPRT-associated purine salvaging is unique for HSCs within primitive hematopoietic stem and progenitor cells. Impaired purine salvaging results in a higher likelihood to enter S-phase and thus in a more active HSC state. We hypothesize that a very critical role of HPRT activity is to reduce the accumulation of toxic purine degradation products to ensure HSCs integrity. 
